ANVS
Annovis Bio, Inc.
NYSE · Healthcare · Biotechnology · US
$1.02
+0.00%Oct 22, 2026, 12:00 UTC
Annovis Bio announced that it will attend and present at the 19th Annovis Bio, Inc. conference in Boston on November 16–19, 2026.
Source:Sep 23, 2026, 12:00 UTC
Annovis Bio announced a collaboration with Weave Bio, an AI regulatory content and knowledge management platform, to support its planned New Drug Application for buntanetap in Alzheimer's disease.
Aug 25, 2026, 12:05 UTC
ANNOVIS BIO announced that its Phase 3 clinical trial for Alzheimer's disease has completed enrollment of all subjects, with key data and regulatory submission expected in 2027.
Source:Aug 14, 2026, 12:00 UTC
Annovis Bio, Inc. reported its financial results for the second quarter ended June 30, 2026.
Source:Jul 7, 2026, 11:00 UTC
Annovis Bio reached full enrollment in its pivotal Phase 3 trial of buntanetap for early Alzheimer's disease.
Source: